Revance Therapeutics (NASDAQ:RVNC – Get Free Report) and CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Profitability
This table compares Revance Therapeutics and CymaBay Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revance Therapeutics | -138.43% | N/A | -45.78% |
| CymaBay Therapeutics | N/A | -50.72% | -31.04% |
Analyst Ratings
This is a summary of recent ratings for Revance Therapeutics and CymaBay Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revance Therapeutics | 0 | 4 | 4 | 0 | 2.50 |
| CymaBay Therapeutics | 0 | 11 | 1 | 0 | 2.08 |
Insider & Institutional Ownership
97.7% of Revance Therapeutics shares are held by institutional investors. Comparatively, 95.0% of CymaBay Therapeutics shares are held by institutional investors. 3.5% of Revance Therapeutics shares are held by company insiders. Comparatively, 7.0% of CymaBay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Revance Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, CymaBay Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Earnings & Valuation
This table compares Revance Therapeutics and CymaBay Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revance Therapeutics | $234.04 million | 1.63 | -$323.99 million | ($3.79) | -0.97 |
| CymaBay Therapeutics | $31.07 million | 119.92 | -$105.37 million | ($0.97) | -33.48 |
CymaBay Therapeutics has lower revenue, but higher earnings than Revance Therapeutics. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Revance Therapeutics beats CymaBay Therapeutics on 8 of the 14 factors compared between the two stocks.
About Revance Therapeutics
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
